Senolytic Prodrug Efficacy Data from Lysosome-Targeted β-Galactoside Compounds

Experimental data details the design and testing of gemcitabine-based galactoside prodrugs for targeting senescent cells. The dataset includes results for the lead compound Gal-dMor-Gem, which achieved a senolytic index of 16.1–56.7 across six senescent cell models, representing a 2.8- to 3.7-fold improvement over a control. It was compiled by Jie Liu and published in 2026.

Use Cases

• Analyze the correlation between prodrug linker modifications (e.g., morpholine groups) and senolytic index values across six cell models.
• Compare drug release kinetics and apoptosis induction rates between Gal-dMor-Gem and the control compound SSK1.
• Model the relationship between prodrug dosage (e.g., 0.5 mg/kg vs. 1.0 mg/kg) and biomarker restoration levels (e.g., SA-β-gal, IL-6, lamin B1) in senescent mice.

Strengths

• Reports a significant senolytic index range of 16.1–56.7 for the lead compound.
• Quantifies a 2.8- to 3.7-fold efficacy improvement over the control drug SSK1.
• Includes results from six distinct senescent cell (SnC) models for validation.

Limitations

• The dataset is very small at 2.0 KB, indicating limited scope and likely a summary of key results rather than raw experimental data.
• No column definitions or sample data are provided, making the data structure and specific variables unclear.
• The data is derived from a specific, controlled research study, limiting its generalizability to other senolytic compounds or biological contexts.

Provenance

Source

Figshare, authored by Jie Liu.

Collection Method

Experimental data from the synthesis and biological testing of designed prodrugs, including cell culture assays and animal studies.

Time Range

null

Freshness

null

Geography

null